Novartis Just Paid $1.1 Billion for a Drug That's Never Been Tested in Humans
Novartis dropped $1.1 billion in cash on a UK startup with zero clinical data and a completely novel ADC payload that's never been tested in humans. The deal structure, the science, and the strategic reversal all tell a fascinating story.
The Check That Raised Every Eyebrow on Wall Street
Novartis just wrote a $1.1 billion check to a UK startup most people have never heard of. The company, Myricx Bio, has no drugs in clinical trials. No patients have ever been dosed with its technology. Its lead programs are still in the preclinical stage, meaning they've only been tested in lab dishes and animals.
And yet Novartis decided this was worth more than a billion dollars upfront, with another $400 million in milestone payments on the table. Total potential price tag: $1.5 billion.
Vontobel analysts called the deal "extraordinary." Fierce Biotech described Myricx as a "little-known biotech with no clinical data." One specialist analysis put it bluntly: Novartis didn't buy a product. It bought a thesis.
So what on earth is this thesis, and why does Novartis think it's worth a king's ransom?
The Weapon Everyone Wants (and Its Growing Problem)
To understand this deal, you need to understand the hottest weapon in cancer treatment right now: the antibody-drug conjugate, or ADC.
Think of an ADC like a guided missile. The antibody is the GPS system; it locks onto a specific protein on the surface of cancer cells. The payload is the warhead; it's a potent toxin designed to kill the cancer cell from the inside. A chemical linker holds the two pieces together until the missile reaches its target.
ADCs have become the most coveted modality in oncology. The top five players (AstraZeneca, Daiichi Sankyo, Pfizer, Roche, and Astellas) control roughly 70% of ADC revenues. Pharma companies are pouring billions into partnerships and acquisitions to get their hands on this technology.
But there's a catch. Almost every ADC on the market or in late-stage trials uses one of two warhead types: tubulin inhibitors or topoisomerase-1 inhibitors. Together, these two payload classes account for about 80% of clinical ADC licensing deals. That's a lot of missiles carrying the same type of bomb.
And tumors are catching on. Some cancers develop resistance to these payloads, the same way bacteria develop resistance to overused antibiotics. When that happens, the guided missile still finds its target, but the warhead doesn't work anymore.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This is the gap Myricx claims it can fill.
A Payload Class Nobody Else Has
Myricx Bio spun out of Imperial College London and the Francis Crick Institute, two of the UK's most prestigious research institutions. Its founders discovered something interesting about an enzyme called N-myristoyltransferase, or NMT.
NMT is basically a cellular locksmith. It attaches a tiny fatty acid (myristic acid) to proteins, which acts like a key card that lets those proteins access specific parts of the cell. Without that key card, the proteins can't reach the membranes, organelles, and signaling hubs where they do their jobs.
This matters because more than 100 human proteins identified through proteomic profiling rely on NMT to function properly. Many of those proteins drive cancer: they fuel growth signaling, help cells dodge death, power metabolism, and keep the cellular machinery running. Cancer cells are especially dependent on this process, almost like a building where every important office requires the same key card to enter.
Block the locksmith, and chaos ensues. Growth signals go dark. Metabolic pathways collapse. The cell's stress responses overwhelm it. Cancer cells, which lean on these pathways more heavily than normal cells, are hit hardest.
Myricx took small-molecule NMT inhibitors and turned them into ADC payloads. Instead of flooding the whole body with an NMT-blocking drug (which is what systemic inhibitors like the clinical-stage PCLX-001 do), Myricx's approach delivers the NMT inhibitor directly to cancer cells via the ADC's antibody guidance system. Precision strike, minimal collateral damage.
The result is a first-in-class ADC payload that works through a completely different mechanism than anything else in the clinic. Myricx calls it "orthogonal" to existing payloads, which is a fancy way of saying: if a tumor has figured out how to survive a topo-1 warhead, our warhead still works because it attacks from a totally different angle.
The Preclinical Data That Opened Novartis's Wallet
Myricx's preclinical results are genuinely striking, even accounting for the usual caveat that mice aren't people.
Their B7-H3-targeted NMTi ADC achieved complete and durable tumor regressions in aggressive prostate cancer models that were resistant to topo-1-based ADCs. Their TROP2-targeted version did the same in breast cancer models, including large, established tumors that had already been exposed to a topo-1 ADC and stopped responding.
Their HER2-targeted NMTi ADC showed strong efficacy alongside encouraging tolerability data in both rodents and non-human primates. Across the board, the company reports a differentiated toxicity profile compared to conventional payloads, suggesting the side effects might look meaningfully different (and potentially more manageable) than what doctors see today.
The platform also appears versatile. Myricx has multiple series of patent-protected NMT inhibitors that are compatible with a range of linkers and straightforward to attach to different antibodies. That flexibility is exactly what makes this a platform acquisition rather than a single-product bet.
Novartis isn't buying one drug candidate. It's buying a new class of warheads it can load onto many different missiles.
Why Novartis, and Why Now?
This is where the story gets really interesting. As recently as January 2024, Novartis CEO Vas Narasimhan stood at the J.P. Morgan Healthcare Conference and essentially said: we're not doing ADC deals.
His reasoning was straightforward. Novartis had tried ADCs internally and failed. The company's competitive edge was in radioligand therapies (a different type of targeted cancer treatment), and it wanted to focus on areas where it could achieve "long-term sustainable leadership." While every other big pharma company was scrambling for ADC assets, Novartis sat out.
Then, two and a half years later, it dropped $1.1 billion on a preclinical ADC platform.
What changed? The answer appears to be differentiation. Novartis didn't want to be the fifth company fighting over topo-1 or tubulin ADC technology. It waited until it found a payload platform that was genuinely novel, one that could complement its existing radioligand therapy franchise rather than compete with established ADC players on their home turf.
Fiona Marshall, Novartis's President of Biomedical Research, said it plainly: ADCs are already important in cancer treatment, but there is "a clear need for new payload mechanisms to overcome resistance and expand their impact for patients."
Late to the ADC party, but arriving with something nobody else has. That's the play.
The Price of Conviction
Let's talk about the money, because the structure of this deal is unusual.
In a typical early-stage biotech acquisition, the buyer hedges its risk. It pays a modest amount upfront and loads the deal with milestone payments (sometimes called "biobucks") that only get paid if the science actually works in humans. This is like putting down a small deposit on a house and making the rest of the payment contingent on the home inspection.
Novartis did the opposite. About 73% of the total deal value ($1.1 billion of $1.5 billion) is guaranteed cash at closing. The milestones are capped at just $400 million. Novartis is essentially saying: we believe in this science enough to absorb nearly all the risk ourselves.
Vontobel analysts flagged this explicitly, noting that the risk profile is elevated given how far the assets are from any potential launch. The economic upside is "long-dated," meaning Novartis won't see returns for years, and it'll need to fund significant R&D spending in the meantime.
For Sofinnova Partners, the European VC firm that backed Myricx, this is a landmark exit and a bright signal for the UK biotech ecosystem. A $1.5 billion acquisition of a London-based, preclinical-stage platform company is the kind of outcome that attracts more capital to the region.
The ADC Arms Race Just Got a New Front
This deal doesn't exist in a vacuum. The ADC landscape in 2025 and 2026 has been defined by an escalating arms race.
AstraZeneca and Daiichi Sankyo's partnership around the DXd payload platform remains the gold standard. Pfizer's Seagen acquisition gave it a massive vedotin-based franchise. The field has been moving beyond traditional ADCs into bispecific ADCs and dual-payload constructs. Industry analysts describe the current moment as a shift from "platform validation" to "platform proliferation."
In that context, Novartis's Myricx bet opens a genuinely new front. Instead of fighting for a bigger share of topo-1 or tubulin territory, Novartis is staking a claim on uncharted ground: NMT inhibition as a payload class that could work precisely where the incumbents fail.
If the thesis holds, Novartis could have a differentiated ADC franchise that complements (rather than competes with) the dominant players. If it doesn't hold, the company will have spent more than a billion dollars on very expensive preclinical data.
The Only Number That Matters Now
Every analyst tracking this deal agrees on one thing: the next inflection point is first-in-human data.
Myricx had been expecting to enter clinical trials in 2026 with a lead NMTi-ADC development candidate. Under Novartis's ownership and funding, that timeline could accelerate. The dose-escalation phase will answer the two questions that preclinical data can only hint at: Does this new payload class work in real patients? And can they tolerate it?
Until then, Novartis has purchased conviction, not proof. The $1.1 billion buys a thesis, a platform, and a head start. Whether it bought a franchise depends entirely on what happens when NMTi-ADCs meet their first human tumor.
For a company that spent two years insisting it didn't need ADCs, that's one hell of a change of heart.
Clinical & Regulatory4 min read
Pfizer Just Found a Way to Bring Color Back
Pfizer's oral pill ritlecitinib just cleared both Phase 3 trials for vitiligo, a condition with almost no approved treatments. If regulators agree, it would be the first oral therapy ever approved to bring color back to depigmented skin.
